Dyadic International, Inc. (DYAI)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 2 | 2 | 3 | 3 | 3 | 1 | 3 | 7 |
| Operating profit | $m | -7 | -7 | ||||||
| Net profit | $m | -9 | -13 | -10 | -7 | -6 | -7 | -8 | -4 |
| EPS reported | $ | -0.23 | -0.21 | ||||||
| Operating cashflow per share | $ | -0.17 | -0.20 | ||||||
| Capex per share | $ | 0.00 | 0.00 | ||||||
| FCF per share | $ | -0.17 | -0.20 | ||||||
| Free cash flow | $m | -6 | -7 | ||||||
| Net debt | $m | -2 | 2 | ||||||
| Book value equity | $m | 1 | -2 | ||||||
| Book value per share | $ | 0.04 | -0.07 | ||||||
| Number of shares | m | 32.62 | 36.44 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 24.88 | -12.85 | ||||||
| P/S LTM | x | 24.89 | 8.83 | ||||||
| P/FCF LTM | x | -5.38 | -4.14 | ||||||
| EV/EBITDA LTM | x | -4.50 | -4.33 | ||||||
| EV/Sales LTM | x | 25.24 | 9.18 | ||||||
| Earnings Yield LTM | % | -24.01% | -26.99% | ||||||
| FCF Yield | % | -18.59% | -24.14% | ||||||
| Quality | |||||||||
| ROE | % | -597.58% | -2918.1% | ||||||
| ROIC | % | -1.14% | -2.79% | ||||||
| Operating margin | % | -5.80% | -2.14% | ||||||
| Gross margin | % | -88.25% | +30.44% | ||||||
| FCF/Sales | % | -462.73% | -213.22% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | -64.74% | -0.66% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -1.13 | -1.47 | ||||||
| Net Debt/EBITDA | x | -0.06 | -0.50 | ||||||
| EBIT/Net interest | x | -15.67 | -17.71 | ||||||
| Net debt/market cap | % | +16.39% | +17.85% | ||||||
| Net debt/Equity | x | -1.86 | -0.81 | ||||||
| Gross debt/equity | x | 4.11 | -2.11 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Dyadic International, Inc. operates as a U.S.-based biotechnology platform company, specializing in the development, production, and commercialization of enzymes and other proteins. Its core activities are underpinned by a patented and proprietary C1 platform, alongside other advanced technologies. This technological foundation drives their research, development, and commercial endeavors, focusing on the creation and manufacturing of various human and animal vaccines and pharmaceutical products. These offerings span a wide range of biological therapeutics, including virus-like particles (VLPs), antigens, monoclonal, bi-specific, and tri-specific antibodies, Fab antibody fragments, Fc-fusion proteins, biosimilars, biobetters, and diverse therapeutic enzymes and proteins. A key pipeline asset is DYAI-100, a SARS-CoV-2-RBD antigen vaccine candidate. This candidate is currently slated for a first-in-human Phase 1 clinical trial, with the objective of establishing proof of concept for the development of next-generation, multivariant COVID-19 vaccine candidates. Dyadic also maintains several strategic alliances, including a research and development agreement with VTT Technical Research Centre of Finland, Ltd., a strategic research services agreement with Biotechnology Developments for Industry in Pharmaceuticals, S.L.U., and a collaboration with Syngene International Limited. Established in 1979, the company is headquartered in Jupiter, Florida.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Dyadic International, Inc. (DYAI)
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Dyadic International, Inc. operates as a U.S.-based biotechnology platform company, specializing in the development, production, and commercialization of enzymes and other proteins. Its core activities are underpinned by a patented and proprietary C1 platform, alongside other advanced technologies. This technological foundation drives their research, development, and commercial endeavors, focusing on the creation and manufacturing of various human and animal vaccines and pharmaceutical products. These offerings span a wide range of biological therapeutics, including virus-like particles (VLPs), antigens, monoclonal, bi-specific, and tri-specific antibodies, Fab antibody fragments, Fc-fusion proteins, biosimilars, biobetters, and diverse therapeutic enzymes and proteins. A key pipeline asset is DYAI-100, a SARS-CoV-2-RBD antigen vaccine candidate. This candidate is currently slated for a first-in-human Phase 1 clinical trial, with the objective of establishing proof of concept for the development of next-generation, multivariant COVID-19 vaccine candidates. Dyadic also maintains several strategic alliances, including a research and development agreement with VTT Technical Research Centre of Finland, Ltd., a strategic research services agreement with Biotechnology Developments for Industry in Pharmaceuticals, S.L.U., and a collaboration with Syngene International Limited. Established in 1979, the company is headquartered in Jupiter, Florida.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free